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Abstract
Background: Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of
care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national reference
network implemented to improve the outcome of sarcoma patients in France since 2010, providing remote access
to specialized diagnosis and Multidisciplinary Tumour Board (MTB). The IGéAS research program aims to assess the
potential of this innovative organization, with remote management of cancers including rare tumours, to go
through geographical barriers usually impeding the optimal management of cancer patients.
Methods: Using the nationwide NETSARC+ databases, the individual, clinical and geographical determinants of the
access to sarcoma-specialized diagnosis and MTB were analysed. The IGéAS cohort (n = 20,590) includes all patients
living in France with first sarcoma diagnosis between 2011 and 2014. Early access was defined as specialised review
performed before 30 days of sampling and as first sarcoma MTB discussion performed before the first surgery.
Results: Some clinical populations are at highest risk of initial management without access to sarcoma specialized
services, such as patients with non-GIST visceral sarcoma for diagnosis [OR 1.96, 95% CI 1.78 to 2.15] and MTB
discussion [OR 3.56, 95% CI 3.16 to 4.01]. Social deprivation of the municipality is not associated with early access
on NETSARC+ remote services. The quintile of patients furthest away from reference centres have lower chances of
early access to specialized diagnosis [OR 1.18, 95% CI 1.06 to 1.31] and MTB discussion [OR 1.24, 95% CI 1.10 to 1.40]
but this influence of the distance is slight in comparison with clinical factors and previous studies on the access to
cancer-specialized facilities.
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Conclusions: In the context of national organization driven by reference network, distance to reference centres
slightly alters the early access to sarcoma specialized services and social deprivation has no impact on it. The
reference networks’ organization, designed to improve the access to specialized services and the quality of cancer
management, can be considered as an interesting device to reduce social and spatial inequalities in cancer
management. The potential of this organization must be confirmed by further studies, including survival analysis.
Keywords: Cancer inequalities, Spatial inequalities, Reference networks, Sarcoma, Cancer care accessibility, Rare
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Introduction
Reference networks have been implemented in several
European countries to improve the management of pa-
tients with rare cancers that require highly specialized
diagnostic and therapeutic management to improve sur-
vival [1, 2]. According to the “hub-and-spoke” model,
the reference networks’ organization is supposed to
structure collaborations between a relatively high num-
ber of centres (spokes) ensuring geographical coverage
and a limited number of reference centres (hubs) which
concentrate the best expertise available, by “virtually
centralizing some services (e.g. pathological diagnosis),
referring some patients for selected procedures (e.g. sur-
gery), directly carrying out other treatments (e.g. medical
therapy), within a clinical strategy continuously shared
with an Multidisciplinary Tumour Board (MTB)” [1, 3].
Sarcomas, which account for 1–3% of all cancers are
paradigmatic models for rare cancers [4–6]. The com-
plexity of these tumours requires a planned, coordinated
and specialized initial management in order to ensure
the best possible management and survival for these pa-
tients [7–10]. Reference networks organizing sarcoma
management are currently operational in Scandinavian
countries as well as in the United Kingdom [11, 12]. At
the European scale, three European reference networks
(ERN) dedicated to rare cancers have been launched in
2017: EuroBloodNet (https://www.eurobloodnet.eu),
PaedCan (http://paedcan.ern-net.eu) and EURACAN
(http://euracan.ern-net.eu). Each ERN brings together
reference expert centres across Europe with a complete
set of multidisciplinary expertise to facilitate the review
of a patient’s diagnosis and treatment
Since the reference networks’ organization supports
better access to expertise, it is important to assess and
measure its potential beneficial effects on inequalities in
cancer management. Previous studies showed worse sur-
vival for patients living in socially deprived and rural
areas that can be related either to their lower rate of re-
ferral or to a later referral to specialized cancer centres
[13–23]. Moreover, patients with rare cancer have worse
survival than patients with common cancer and suffer
from the lower accessibility of specialized facilities [24,
25]. By reducing the effects of barriers related to the pa-
tients’ place of residence, such as social deprivation and
remoteness, which usually impede the early access to
specialized services, the reference networks’ organization
could therefore reduce inequalities in the cancer
management.
In France, the sarcoma pathology (RRePS) and clinical
(NetSarc) networks for visceral and soft tissue sarcomas
were launched in 2010 and have been subsequently
joined by RESOS focused on bone sarcomas. These three
networks have since merged in a single NETSARC+ net-
work, gathering together more than 30 reference centres.
Following ESMO-EURACAN Clinical Practice Guide-
lines, each new sarcoma diagnosis should benefit from
histological review and MTB discussion within a NETS
ARC+ centre during first-line management [26]. Remote
access to these specialized services can be delivered
thanks to the request of practitioners or facilities man-
aging the patients.
Previous publications report the better compliance to
international clinical guidelines, quality of initial man-
agement within the reference centres and its benefit on
patients’ survival [7, 8, 27]. The IGéAS research program
was designed to assess the ability of this national refer-
ence network to reduce geographical inequalities during
the cancer management [25]. Using national sarcoma
reference networks databases, the individual, medical
and geographical factors associated with the early access
to specialized services within the French sarcoma refer-
ence network NETSARC+ were analysed to determine
whether sarcoma patient really benefit from this policy.
Methods
National sarcoma networks databases
All patients with specialized diagnosis and/or MTB dis-
cussion within a reference centre since 2010 are regis-
tered in a curated online national database approved by
national health authorities (CNIL, n°910,390) (https://
netsarc.sarcomabcb.org/). The databases contain 60
items divided into four themes: characteristics of the pa-
tient and tumour, diagnosis and review, key steps in
management and follow-up, and successive presenta-
tions of the file and decision making at MTB. The muni-
cipality of patient, diagnosis and clinical data as well as
patient follow-up are collected. A quality assurance pro-
gram has been established for these databases to ensure
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the quality of medical data recorded, and clinical follow-
up information is updated at least every 2 years.
Constitution and analysis of the IGéAS cohort
The complete methodology of the IGéAS research pro-
gram and description of the IGéAS cohort (n = 20,589)
have been previously published [25]. The inclusion and
exclusion criteria for the present work were as follow:
patient living in France at time of diagnosis, diagnosis of
sarcoma/GIST/desmoid tumour/intermediate malig-
nancy tumour between the 1st of January 2011 and the
31th of December 2014. According to national sarcoma
guidelines and the data collected in the NETSARC+
database, the steering committee of IGéAS research pro-
gram has defined as follows:
1) Early access to specialized diagnosis as initial
diagnosis or review performed in reference
networks’ centres before 30 days of sampling
2) Early access to MTB discussion within NETSARC+
as first sarcoma MTB performed before the first
surgery (open biopsy excluded). Radiation and/or
chemotherapy used as neoadjuvant or even
exclusive lines of therapy were considered as initial
management.
Other patients who subsequently had access to review
or MTB in the aftermath were recorded as late access.
Statistical analysis
Univariate and multivariate analyses, following a binary
logistic regression model, were performed to identify the
factors associated with late access or no access to spe-
cialized diagnosis and clinical services. A total of 1837
patients (bone sarcoma diagnosis in 2011 and 2012 and
patients under 18 years of age) of the IGéAS cohort were
excluded from univariate and multivariate analyses be-
cause the corresponding populations was just partially
recorded in the databases and might introduce some po-
tential bias. Overseas patients were also excluded due to
the lack of geographical data in overseas territories, lim-
iting the calculation of geographical indices. As a result,
univariate and multivariate analyses were done on 18,
264 mainland patients. We provide descriptive analysis
to assess the access to sarcoma specialized services in
French overseas territories in comparison to mainland
France (Fig. 1).
Fig. 1 Flowchart of the constitution of the IGéAS cohort and data analyses
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The univariate analyses used individual variables (sex,
age) and clinico-pathological variables (past medical his-
tory, tumour size, pathological type, subtype and grade,
depth of tumour, localization, year of diagnosis). For the
“type of tumour” variable, we separated Gastro-Intestinal
and Stromal Tumours (GIST) from other visceral sar-
coma considering the specificities of GIST that have
usually better prognosis. Using the patient’s municipality
of residence at diagnosis, some validated geographic in-
dices measuring the patients’ life context were also in-
cluded: region, GeoClasH classification of the French
municipalities [28], European Deprivation Index [29],
population density [28], travel time to the closest refer-
ence pathological centre [25], travel time to the closest
reference clinical centre, travel time to the closest gen-
eral hospital [25] and localized potential accessibility
index measuring spatial accessibility to general practi-
tioners [30, 31]. Social information about the patients is
not available in the NETSARC+ database to study the
influence of social deprivation at the individual level.
All statistical analyses were performed using SAS soft-
ware, version 9.4 (SAS Institute, Cary, USA). The candi-
date variables for the multivariate model were those
with a p-value of less than 0.20 in univariate and with
less than 20% missing data. Variables whose p-values
were highlighted in grey were included in the multivari-
ate analysis. All these variables are input into the model
and then selected step by step (backward stepwise selec-
tion). The final model contains the variables that remain
significant with a p < 0.05. Separated models with only
clinical and geographical variables were finally per-
formed to compare the respective impact of clinical and
geographical variables on the access to the reference net-
works’ services. The adequacy and discrimination of the
models were checked with the Akaiké Information Cri-
terion (AIC), the percentage of well ranked and the area
under the curve (0.5 indicates low discrimination and 1
indicates perfect discrimination).
Results
Comparison of the access to sarcoma specialized
diagnosis and MTB between patients living in mainland
France and overseas patients (IGéAS cohort)
A total of 11,642 of 20,101 (57.9%) and 199 of 488
(40.8%) sarcoma patients, respectively living in mainland
France and the overseas territories, had access to a spe-
cialized diagnosis within Netsarc+ within 30 days of
sampling (Table 1). A total of 6195 of 20,101 (30.8%)
and 122 of 488 (25%) sarcoma patients, respectively from
mainland France and overseas territories, had access to a
specialized MTB within Netsarc+ before the first
surgery.
Determinants of the initial management without access
to sarcoma specialized diagnosis within Netsarc+
Sex, age, year of diagnosis, type, size, grade of tumour,
geographic region and travel time to the closest refer-
ence centre for sarcoma diagnosis are associated with
higher risk of initial management without access to sar-
coma specialized diagnosis in Netsarc+ reference cen-
tres, in the final multivariate model (Table 2). Some
clinical populations are at higher risk such as patients
with non-GIST visceral sarcomas [OR 1.96, 95% CI 1.78
to 2.15] and patients with not graded sarcomas, accord-
ing to the WHO classification of tumours [32] [OR 1.83,
95% CI 1.61 to 2.10]. We find no association with social
deprivation and the farthest 20% of patients (more than
97min of travel time to the closest reference centre for
sarcoma diagnosis) have 18% higher risk of initial man-
agement without access to sarcoma specialized diagnosis
[OR 1.18, 95% CI 1.06 to 1.31].
Determinants of the initial management without access
to sarcoma specialized MTB within Netsarc+
Age, year of diagnosis, type of tumour, depth, size of
tumour, histotype category, grade, geographic region
and travel time to the closest reference centre are associ-
ated with higher risk of late access or no access to sar-
coma specialized MTB in Netsarc+ reference centres, in
the final multivariate model (Table 3). The probability of
optimal access to specialized MTB increased over time
during the observation period (p < 0.0001). Some clinical
populations are at higher risk such as patients with non-
GIST visceral sarcoma [OR 3.56, 95% 3.16 to 4.01], with
superficial [OR 2.15, 95 CI% 1.83 to 2.54] or less than
50mm sized tumour s [OR 2.58, 95 CI% 2.23 to 2.98].
We found no association with social deprivation and the
farthest 20% of patients (more than 102 min of travel
time to the closest sarcoma reference centre) have 24%
Table 1 Access to sarcoma specialized services within Netsarc+ for French patients from 2011 to 2014 including overseas territories
patients (source: IGéAS cohort, RRePS – ResOs – NETSARC databases)
Access to specialized diagnosis Access to specialized MTB
Early access Late access No access Early access Late access No access
Mainland France (n = 20,101) N = 11,642 (57.9%) N = 4778 (23.8%) N = 3681 (18.3%) N = 6195 (30,8%) N = 6905 (34,3%) N = 7001 (34,8%)
Overseas territories (n = 488) N = 199
(40.8%)




N = 140 (28,7%) N = 226 (46,3%)
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Table 2 Determinants of late access or no access to sarcoma specialized diagnosis within Netsarc+ from 2011 to 2014 (source:
IGéAS cohort, RRePS – ResOs – NETSARC databases)
Univariate (N = 18,264) Multivariate (N = 18,264)
Variables late or no access / early access OR IC 95% p-value OR IC 95% p-value
Individual and clinical variables
Sex <.0001 0.0048
Male 3562/5656 1 1
Female 3918/5128 1.21 [1.14;1.28] 1.09 [1.02;1.16]
Age <.0001 0.0249
> =75 1622/2711 1 1
[18–25[ 261/373 1.17 [0.98;1.38] 0.98 [0.82;1.18]
[25–50[ 1959/2536 1.29 [1.18;1.40] 1.12 [1.03;1.23]
[50–75[ 3638/5164 1.17 [1.09;1.26] 1.10 [1.02;1.19]
Year of diagnosis 0.0018 0.0061
2011 1601/2315 1 1
2012 1706/2501 0.98 [0.90;1.07] 0.95 [0.87;1.04]
2013 1949/3017 0.93 [0.85;1.01] 0.9 [0.82;0.98]
2014 2224/2951 1.09 [1.00;1.18] 1.03 [0.95;1.13]
Type of tumour <.0001 < 0.0001
Soft tissue 4666/7594 1 1
Bone 474/578 1.33 [1.17;1.51] 1.10 [0.96;1.26]
Viscera – GIST 917/1520 0.98 [0.89;1.07] 1.11 [0.99;1.26]
Viscera - No GIST 1423/1092 2.12 [1.94;2.31] 1.96 [1.78;2.15]
Depth of tumour 0,0007
Superficial and deep 394/650 1
Superficial 1526/2376 1.06 [0.92;1.22]
Deep 4865/6873 1.16 [1.02;1.33]
Missing 695/885 1.29 [1.10;1.52]
Size of tumour <.0001 < 0.0001
> =200 475/873 1 1
[50–200[ 3304/5008 1.21 [1.07;1.36] 1.15 [1.02;1.31]
[0–50[ 2236/3294 1.24 [1.10;1.41] 1.30 [1.14;1.48]
Missing 1465/1609 1.67 [1.46;1.91] 1.51 [1.31;1.74]
Histotype category <.0001
GIST 983/1621 1
Sarcoma 4657/6179 1.24 [1.13;1.35]
Tumour of intermediate malignancy 1840/2984 1.01 [0.92;1.12]
Grade <.0001 < 0.0001
1 749/1201 1 1
2 2312/3784 0.98 [0.88;1.08] 0.89 [0.80;0.99]
3 1266/1887 1.07 [0.95;1.20] 1.02 [0.91;1.15]
Not applicable 1236/876 2.26 [1.99;2.56] 1.83 [1.61;2.10]
Missing 1917/3036 1.01 [0.90;1.12] 0.93 [0.82;1.06]
Geographical variables
Region <.0001 < 0.0001
Auvergne-Rhône-Alpes 1013/1319 1 1
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Table 2 Determinants of late access or no access to sarcoma specialized diagnosis within Netsarc+ from 2011 to 2014 (source:
IGéAS cohort, RRePS – ResOs – NETSARC databases) (Continued)
Univariate (N = 18,264) Multivariate (N = 18,264)
Variables late or no access / early access OR IC 95% p-value OR IC 95% p-value
Nouvelle-Aquitaine 564/1527 0.48 [0.42;0.54] 0.46 [0.40;0.52]
Pays-de-la-Loire 327/709 0.60 [0.51;0.70] 0.60 [0.51;0.71]
Centre-Val de Loire 233/470 0.64 [0.54;0.77] 0.64 [0.54;0.77]
Provence-Alpes-Côte-d’Azur 656/1241 0.68 [0.60;0.78] 0.69 [0.61;0.79]
Bretagne 339/659 0.67 [0.57;0.78] 0.70 [0.59;0.82]
Corse 46/76 0.78 [0.54;1.14] 0.72 [0.49;1.07]
Occitanie 672/1131 0.77 [0.68;0.87] 0.78 [0.69;0.89]
Bourgogne-Franche-Comté 333/538 0.80 [0.68;0.94] 0.83 [0.70;0.97]
Grand-Est 732/838 1.13 [1.00;1.29] 1.18 [1.04;1.35]
Hauts-de-France 737/744 1.29 [1.13;1.47] 1.31 [1.14;1.50]
Normandie 301/287 1.36 [1.13;1.63] 1.43 [1.18;1.72]
Ile-de-France 1527/1245 1.59 [1.42;1.78] 1.77 [1.57;2.00]
GeoClasH classification of municipalities <.0001
Wealthy Metropolitan Areas 1824/2071 1
Precarious Population Districts 3837/5748 0.75 [0.70;0.81]
Residential Outskirts 913/1394 0.74 [0.67;0.82]
Agricultural and Industrial Plains 582/968 0.68 [0.60;0.77]
Rural Margins 324/603 0.61 [0.52;0.70]
Travel time to the closest reference centre for sarcoma diagnosis in minutes, quintiles) <.0001 0.0073
< = 21 1581/2119 1 1
] 21; 47.5] 1548/2082 0.99 [0.90;1.09] 1.05 [0.95;1.16]
] 47.5; 73.5] 1484/2187 0.90 [0.82;0.99] 1.10 [0.99;1.21]
] 73.5; 97.5] 1491/2125 0.94 [0.85;1.03] 1.18 [1.06;1.31]
> 97.5 1376/2271 0.81 [0.74;0.89] 1.18 [1.06;1.31]
European Deprivation Index (quintiles) < 0.0001
< = − 1.3 (least deprived) 1478/2188 1
]-1.3; 1.8] 1386/2227 0.92 [0.83;1.01]
]1.8; 5.6] 1438/2248 0.94 [0.86;1.04]
]5.6; 9.2] 1501/2218 1.00 [0.91;1.09]
> 9.2 (most deprived) 1677/1903 1.30 [1.18;1.43]
Population density (number of inhabitants/km2, quintiles) < 0.0001
< = 94.0926 1364/2304 1
] 94.0926; 306.127] 1399/2226 0.68 [0.62;0.74]
] 306.127; 1034.61] 1462/2184 0.72 [0.65;0.79]
] 1034.61; 3693.94] 1547/2104 0.77 [0.70;0.84]
> 3693.94 1708/1966 0.84 [0.77;0.92]
APL index (spatial accessibility to general practitioners, quintiles) < 0.0001
< = 49.1 (lowest accessibility) 1528/2094 1
] 49.1; 64] 1707/1973 1.18 [1.08;1.30]
] 64; 78.4] 1408/2142 0.90 [0.82;0.99]
] 78.4; 90.7] 1403/2345 0.82 [0.74;0.90]
> 90.7 (highest accessibility) 1434/2230 0.88 [0.80;0.96]
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Table 3 Determinants of the late access (after first surgery) or no access to sarcoma specialized MTB within Netsarc+ from 2011 to
2014 (source: IGéAS cohort, RRePS – ResOs – NETSARC databases)
Univariate (N = 18,264) Multivariate (N = 18,264)
Variables late or no access / early access OR IC 95% p-value OR IC 95% p-value
Individual and clinical variables
Sex 0.0093
Male 6421/2797 1
Female 6460/2586 1.08 [1.02;1.16]
Age < 0.0001 < 0.0001
[18–25] 335/299 1 1
[25–50] 2988/1507 1.77 [1.49;2.09] 1.33 [1.10;1.60]
[50–75] 6286/2516 2.23 [1.89;2.62] 1.65 [1.38;1.99]
> =75 3272/1061 2.75 [2.32;3.26] 1.85 [1.52;2.25]
Year of diagnosis < 0.0001 < 0.0001
2011 2972/944 1 1
2012 3034/1173 0.82 [0.74;0.90] 0.78 [0.70;0.87]
2013 3390/1576 0.68 [0.62;0.75] 0.79 [0.71;0.88]
2014 3485/1690 0.65 [0.59;0.71] 0.68 [0.61;0.75]
Type of tumour < 0.0001 < 0.0001
Soft tissue 8187/4073 1 1
Bone 415/637 0.32 [0.28;0.36] 0.35 [0.29;0.42]
Viscera – GIST 2190/247 4.41 [3.84;5.05] 1.99 [1.32;3.00]
Viscera - No GIST 2089/426 2.44 [2.18;2.72] 3.56 [3.16;4.01]
Depth of tumour < 0.0001 < 0.0001
Superficial and deep 667/377 1 1
Superficial 3312/590 3.17 [2.721;3.7] 2.15 [1.83;2.54]
Deep 7903/3835 1.16 [1.02;1.32] 0.82 [0.71;0.95]
Missing 999/581 0.97 [0.82;1.14] 1.35 [1.09;1.66]
Size of tumour < 0.0001 < 0.0001
> =200 707/641 1 1
[50–200] 5242/3070 1.54 [1.37;1.73] 1.40 [1.24;1.59]
[0–50] 4486/1044 3.89 [3.43;4.42] 2.58 [2.23;2.98]
Missing 2446/628 3.53 [3.07;4.05] 2.80 [2.39;3.28]
Histotype category < 0.0001 < 0.0001
Sarcoma 6809/4027 1 1
GIST 2323/281 4.88 [4.29;5.56] 1.43 [0.96;2.14]
Tumour of intermediate malignancy 3749/1075 2.06 [1.90;2.23] 2.07 [1.87;2.30]
Grade < 0.0001 < 0.0001
1 1204/746 1 1
2 4373/1723 1.57 [1.41;1.75] 1.01 [0.90;1.10]
3 1771/1382 0.79 [0.70;0.89] 0.92 [0.81;1.05]
Not applicable 1304/808 1 [0.88;1.13] 0.94 [0.81;1.10]
Missing 4229/724 3.61 [3.20;4.08] 2.59 [2.22;3.02]
Geographical variables
Region < 0.0001 < 0.0001
Auvergne-Rhône-Alpes 1556/776 1 1
Fayet et al. BMC Cancer          (2021) 21:631 Page 7 of 12
Table 3 Determinants of the late access (after first surgery) or no access to sarcoma specialized MTB within Netsarc+ from 2011 to
2014 (source: IGéAS cohort, RRePS – ResOs – NETSARC databases) (Continued)
Univariate (N = 18,264) Multivariate (N = 18,264)
Variables late or no access / early access OR IC 95% p-value OR IC 95% p-value
Grand-Est 1051/519 1.01 [0.88;1.15] 0.91 [0.78;1.06]
Nouvelle-Aquitaine 1457/634 1.14 [1.00;1.30] 0.93 [0.81;1.08]
Bourgogne-Franche-Comté 594/277 1.06 [0.90;1.26] 0.94 [0.78;1.13]
Centre-Val de Loire 484/219 1.10 [0.91;1.32] 0.98 [0.80;1.20]
Pays-de-la-Loire 718/318 1.12 [0.96;1.31] 0.98 [0.82;1.17]
Occitanie 1242/561 1.10 [0.96;1.26] 1.05 [0.91;1.21]
Hauts-de-France 1024/457 1.11 [0.97;1.28] 1.08 [0.93;1.27]
Ile-de-France 1991/781 1.27 [1.12;1.43] 1.12 [0.97;1.29]
Bretagne 761/237 1.60 [1.35;1.89] 1.31 [1.09;1.59]
Normandie 420/168 1.24 [1.02;1.52] 1.34 [1.08;1.67]
Provence-Alpes-Côte-d’Azur 1485/412 1.79 [1.56;2.06] 1.52 [1.31;1.77]
Corse 98/24 2.03 [1.29;3.20] 1.57 [0.95;2.58]
GeoClasH classification of municipalities 0.1696
Wealthy Metropolitan Areas 2763/1132 1
Precarious Population Districts 6758/2827 0.97 [0.90;1.06]
Residential Outskirts 1586/721 0.90 [0.80;1.00]
Agricultural and Industrial Plains 1122/428 1.07 [0.94;1.22]
Rural Margins 652/275 0.97 [0.83;1.13]
Travel time to the closest sarcoma reference centre (in minutes, quintiles) 0.004 0.0013
< = 29 2576/1168 1 1
[ 29; 56] 2555/1069 1.08 [0.98;1.19] 1.12 [1.00;1.25]
[ 56; 79] 2561/1122 1.03 [0.93;1.14] 1.07 [0.96;1.20]
[ 79; 102] 2507/1009 1.12 [1.01;1.24] 1.21 [1.08;1.36]
> 102 2682/1015 1.19 [1.08;1.32] 1.24 [1.10;1.40]
European Deprivation Index (quintiles) 0.04
< = − 1.3 (least deprived) 2551/1115 1
[-1.3; 1.8] 2527/1086 1.01 [0.92;1.12]
[1.8; 5.6] 2648/1038 1.11 [1.00;1.23]
[5.6; 9.2] 2584/1135 0.99 [0.90;1.09]
> 9.2 (most deprived) 2571/1009 1.11 [1.00;1.23]
Population density (number of inhabitants/km2, quintiles) 0.8876
< = 94.0926 2579/1089 1
[ 94.0926; 306.127] 2541/1084 0.99 [0.89;1.09]
[ 306.127; 1034.61] 2566/1080 1.00 [0.90;1.10]
[ 1034.61; 3693.94] 2597/1054 1.04 [0.94;1.15]
> 3693.94 2598/1076 1.02 [0.92;1.12]
APL index (spatial accessibility to general practitioners, quintiles) 0.8087
< = 49.1 (lowest accessibility) 2546/1076 1
[ 49.1; 64] 2575/1105 0.98 [0.89;1.08]
[ 64; 78.4] 2517/1033 1.03 [0.93;1.14]
[ 78.4; 90.7] 2666/1082 1.04 [0.94;1.15]
> 90.7 (highest accessibility) 2577/1087 1.00 [0.90;1.10]
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higher risk [OR 1.24, 95% CI 1.10 to 1.40] of initial man-
agement without access to sarcoma specialized MTB.
Respective impact of clinical and geographical variables
on the access to reference networks’ services
Table 4 shows that models with only clinical (AIC = 24,
149, 59.8% of well ranked observations, AUC = 0.59) or
geographical variables (AIC = 24,116, 59.6% of well
ranked observations, AUC = 0.60) have nearly the same
quality to analyse the optimal access to specialized diag-
nosis in reference centres. These specific models are also
less performative than the model with all (i.e. clinical
and geographical) the variables (AIC = 23,258, 65.3% of
well ranked observations, AUC = 0.65). Considering the
access to specialized MTB, the quality of the model with
only clinical variables (AIC = 18,910, 75.8% of well
ranked observations, AUC = 0.75) is higher than the
model with only geographical variables (AIC = 22,050,
53.9% of well ranked observations, AUC = 0.55) and is
close to the model gathering all the variables (AIC = 18,
852, 76.2% of well ranked observations, AUC = 0.76).
Discussion
This study assessed the ability of the reference networks’
organizations, initially implemented to improve quality
management and survival of rare cancers patients [8], to
address in the same time some public health and social
issues. Our aim was to provide a nationwide overview of
the inequalities in the cancer management, in the spe-
cific setting of an accredited reference networks for rare
cancers patients. A dedicated cohort was built for this
study by cross-referencing databases recording patho-
logical review and specialized MTB in reference centres
to identify as many sarcoma patients as possible and find
out under which conditions they were able to benefit or
not from the expertise of the reference centres. Even if
the databases of the French sarcoma reference networks
support to reconsider upwards the incidence of sarco-
mas [5], only patients who have benefited from a patho-
logical review or a discussion in sarcoma specialized
MTB are recorded into the Netsarc+ databases. All inci-
dent sarcoma patients in France are therefore not in-
cluded in this study, but we estimate the IGéAS cohort
covers at least 90% of the national population [33]. Des-
pite this limitation, our study is based on nationwide
data gathering twenty thousand patients over 4 years
and recording few dozens of individual and clinical in-
formation, which is quite original for rare cancers
studies.
The slight influence of social deprivation and distance to
reference centres
In the context of national organization driven by refer-
ence network, distance to reference centres slightly alters
the early access to sarcoma specialized services and so-
cial deprivation has no impact on it. This is an original
finding with regards to the literature data on spatial in-
equalities in the cancer management [20, 21, 34–36].
For example, a nationwide study in the United States
performed by Onega reported that “the most influential
determinants of NCI-CC attendance were travel-time,
place of residence, particularly for African Americans,
and predominant type of care before diagnosis” rather
than clinical factors included into the analysis like can-
cer site (breast, lung, colorectal or prostate cancer) or
stage at diagnosis [36]. In the present study, the social
deprivation of the municipalities has no impact on the
early access to reference networks’ services. The use of
deprivation indices at the IRIS (infra-municipality) scale
or social information at the individual level would have
supported a more accurate analysis of social inequalities
but was not possible with available databases.
The distance to the nearest reference centre influences
the access to specialized diagnosis and MTB but to a
lesser extent in comparison with previous studies on the
access to cancer-specialized facilities [20, 21, 36, 37]. In-
deed, we found that patients living at more than 102 min
to the closest reference centre have 18.3 and 24.4%
higher risk of initial management without access to re-
spectively sarcoma specialized diagnosis and MTB. As a
Table 4 Adequacy and discrimination parameters of the different logistic regression models (source: IGéAS cohort, RRePS – ResOs –
NETSARC databases)
Models Details AIC Well-ranked % AUC
Optimal access to diagnosis All variables 23,258 65.3 0.65
Optimal access to diagnosis Clinical variables 24,149 59.8 0.59
Optimal access to diagnosis Geographical variables 24,116 59.6 0.60
Optimal access to MTB All variables 18,852 76.2 0.76
Optimal access to MTB Clinical variables 18,910 75.8 0.75
Optimal access to MTB Geographical variables 22,050 53.9 0.55
AIC (Akaike Information Criterion): The model to choose has the smallest AIC
Well-ranked %: The model to choose has the highest %
AUC (Area Under the Curve, from 0 to 1): The model to choose has the highest value
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comparison, Onega reported a decreased likelihood of
11% to attend NCI-Cancer Centre for every 10 min of
added travel-time [OR 0.89, 95% CI 0.88 to 0.90] in the
United States [36]. In France, where transportation costs
can only be partially covered if the patient does not go
to a local facility, Gentil showed that patients living
more than 35min away from the nearest reference care
centre were 62% less likely [OR = 0.38, 95% CI 0.29;
0.50] to be operated on by a specialized surgeon than
patients living less than 10min away [21].
Regional inequalities in the early access to reference
networks’ services must be cautiously interpreted be-
cause it could be related to heterogeneous practices in
the databases’ recording depending on the reference
centre, its intern organization and its own resources. It
could also reflect the variable commitment of practi-
tioners in this new structuring organization. Updating
the regional inequalities on the basis of recent data
would be relevant to determine whether this
organization actually implies novel geographical inequal-
ities at the regional scale, according to the variable ad-
herence of local practitioners. Specific analysis and
dedicated measures are needed to improve collabora-
tions and networking between local facilities and refer-
ence centres in some regions as well as in the overseas
territories, which suffer from the lack of reference cen-
tres on site.
Considering the specificities of sarcomas as well as the
lower spatial accessibility of sarcoma reference centres
in comparison to facilities usually managing cancers [25,
38], increased inequalities in the access to services may
have been expected if reference networks were not im-
plemented. Previous spatial analysis showed the large
geographical coverage of the French sarcoma reference
centres that are often requested to review specimens or
to discuss therapeutic strategy of patients living several
hundred kilometres away [25]. With regards to the lit-
erature, our results confirm the potential of reference
networks to reach socially deprived and remote popula-
tions who usually suffer from the lower quality of their
cancer management.
Key insights to structure and improve the access to
reference networks’ services
National recommendations of mandatory early path-
ology review and MTB discussion in a reference centre
for all sarcoma diagnosis are not always complied with.
Understanding and addressing the causes of this partial
compliance with the national recommendations is a pri-
ority to improve the efficiency of the organization and
the patients’ outcomes [39].
The overriding impact of the clinical factors on the ac-
cess to sarcoma reference networks’ services suggests
that first-line practitioners refer their patients to
reference centres according to the clinical setting of their
patients. According to guidelines, all new sarcoma diag-
nosis should benefit from a specialized pathological diag-
nosis as well as a specialized MTB within a NETSARC+
centre. First-line practitioners may probably consider
that the early use of the reference networks’ services is
not always necessary depending on their evaluation of
the clinical situation of the patient and may be con-
cerned that it will delay the management of sarcoma pa-
tients. This unframed practice of selection by non-
specialist sarcoma practitioners led to an underuse of
the reference networks’ services and can have serious ef-
fects in the management of patients.
Moreover, dedicated actions should target specific
populations that suffer from an insufficient access to sar-
coma expertise. For example, patients with non-GIST
visceral sarcoma have much higher risk of late or no ac-
cess to sarcoma specialized diagnosis and MTB within
NETSARC+, while these sarcomas are particularly ag-
gressive (only 55% 3-year survival rate in the IGéAS co-
hort). This finding could be related to the management
of cancer based on their anatomical location or manage-
ment through “organ-specific” health care management
organization, which refer only secondarily patients to the
sarcoma network after changes of histological diagnosis.
Conclusion
In the context of national organization driven by refer-
ence network, geographical characteristics (social
deprivation, remoteness) usually impeding the optimal
management of cancers patients have much lower im-
pact on the access to specialized services. While many
countries are struggling to address cancer inequalities,
the potential of the reference networks’ organization to
reduce of inequalities in the cancer management must
be confirmed by further studies, including survival
analysis.
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